Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23554702 | 1.00 | DDB1 (0.37) | DDB1CRBNBACE1DGAT1FNTA | |
| SCHEMBL29189520 | 0.85 | CRBN (0.33) | DDB1CRBN | |
| SCHEMBL25704564 | 0.81 | DGAT1 (0.34) | DDB1CRBNDGAT1FNTAFNTB | |
| SCHEMBL30304182 | 0.81 | AKR1B1 (0.34) | DDB1CRBNBACE1 | |
| SCHEMBL24823074 | 0.81 | AKR1B1 (0.34) | DDB1CRBNBACE1 | |
| SCHEMBL23554706 | 0.78 | GAA (0.41) | DDB1CRBNBACE1 | |
| SCHEMBL23554694 | 0.78 | GAA (0.41) | DDB1CRBNBACE1 | |
| SCHEMBL30159906 | 0.78 | GAA (0.41) | DDB1CRBNBACE1 | |
| SCHEMBL30160107 | 0.78 | GAA (0.41) | DDB1CRBNBACE1 | |
| SCHEMBL23532042 | 0.74 | FNTA (0.46) | DDB1CRBNFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317740-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4359079-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International S.A. (CH) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022268890-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317740-A1 | NOVEL COMPOUNDS AND THEIR USE | PGLS, LSS, LAS1L | DDB1 2172/4885CRBN 3202/4885BACE1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.